OTCEastern Europe Report From IMS
Combined over-the-counter drug sales in the Czech Republic, Hungary, Poland and the Slovak Republic will rise to $1.25 billion by 2001 from $713 million in 1995, forecasts IMS SelfMedication International's new OTCEastern Europe study.
Poland is by far the largest market of the four with 53% of the regional total in 1995, and is forecast to show the highest compound annual growth rate, at 11.7% during 1996-2001. Next is Hungary, with 23% of regional dollar sales, and a CAGR of 3.3% in the forecast period, but it is expected to be overtaken by the Czech Republic after 2001. In local currency, Hungary's CAGR is put at 14.2%, with Poland still leading on 26%.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze